Sigurdur Olafsson appointed CEO of Hikma
Hikma Pharmaceuticals today announces its Board of Directors has appointed Sigurdur (Siggi) Olafsson as Chief Executive Officer. Mr Olafsson will also join Hikmas Board of Directors as an executive director, subject to election at the next annual general meeting in May 2018.
Said Darwazah, Hikmas current Chairman and CEO, will assume the position of Executive Chairman.
We are delighted that Siggi is joining Hikma as our new CEO, said Said Darwazah. He brings a wealth of pharmaceutical and leadership experience and we are confident that his deep sector knowledge, paired with his proven ability to drive growth, will help us achieve our ambitions for the business.
As CEO, Mr Olafsson will be responsible for the effective development and execution of Hikmas corporate strategy, focusing on opportunities to accelerate growth of the global business. All members of Hikmas Executive Committee will report to Mr Olafsson, who will report to Mr Darwazah. He will initially be based in the US before relocating to Hikmas head office in London.
NOD-Proteindesign.Andreas Heddergott/TUM.jpg
Certest
Consilium